Prostate Cancer and Prostatic Diseases - Table of Contents alert Volume 21 Issue 3

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 21, Issue 3 In this issue Review Article Article Review Article Article Correspondence Also new AOP   Advertisement We are pleased to announce that the Impact Factor* for Prostate Cancer and Prostatic Diseases is now 4.099 - an increase of 10% from last year. Prostate Cancer and Prostatic Diseases is ranked 11 of 76 in the Urology & Nephrology category and 68 of 222 in the Oncology category. The journal would like to thank all our authors, reviewers and readers for their continued support.  Submit your research >>>  *2017 Journal Citation Reports (Clarivate Analytics, 2018)     Review Article Prostate cancer diagnosis and characterization with mass spectrometry imaging Annika Kurreck, Lindsey A. Vandergrift, Taylor L. Fuss, Piet Habbel, Nathalie Y. R. Agar et al. Prostate Cancer and Prostatic Diseases 2017 21 :297 - 305; December 05, 2017; 10.1038/s41391-017-0011-z   Abstract | Full Text The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation Megan McNamara, Christopher Sweeney, Emmanuel S. Antonarakis & Andrew J. Armstrong Prostate Cancer and Prostatic Diseases 2017 21 :306 - 318; December 20, 2017; 10.1038/s41391-017-0014-9   Abstract | Full Text Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose–response meta-analysis Joe L. Rowles III, Katherine M. Ranard, Catherine C. Applegate, Sookyoung Jeon, Ruopeng An et al. Prostate Cancer and Prostatic Diseases 2018 21 :319 - 336; January 09, 2018; 10.1038/s41391-017-0005-x   Abstract | Full Text Does the association of prostate cancer with night-shift work differ according to rotating vs. fixed schedule? A systematic review and meta-analysis Jennifer Mancio, Cátia Leal, Marta Ferreira, Pedro Norton & Nuno Lunet Prostate Cancer and Prostatic Diseases 2018 21 :337 - 344; April 27, 2018; 10.1038/s41391-018-0040-2   Abstract | Full Text The microbiome in prostate inflammation and prostate cancer Corey M. Porter, Eva Shrestha, Lauren B. Peiffer & Karen S. Sfanos Prostate Cancer and Prostatic Diseases 2018 21 :345 - 354; May 23, 2018; 10.1038/s41391-018-0041-1   Abstract | Full Text Article Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance Glenn T. Werneburg, Michael Kongnyuy, Daniel M. Halpern, Jose M. Salcedo, Kaitlin E. Kosinski et al. Prostate Cancer and Prostatic Diseases 2017 21 :355 - 363; December 07, 2017; 10.1038/s41391-017-0004-y   Abstract | Full Text Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade Rana R. McKay, Bruce Montgomery, Wanling Xie, Zhenwei Zhang, Glenn J. Bubley et al. Prostate Cancer and Prostatic Diseases 2017 21 :364 - 372; December 20, 2017; 10.1038/s41391-017-0009-6   Abstract | Full Text Review Article Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort Ville Kukko, Antti Kaipia, Kirsi Talala, Kimmo Taari, Teuvo L. J. Tammela et al. Prostate Cancer and Prostatic Diseases 2017 21 :373 - 378; December 22, 2017; 10.1038/s41391-017-0031-8   Abstract | Full Text Article Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience Daniel Mollengarden, Kenneth Goldberg, Daniel Wong & Claus Roehrborn Prostate Cancer and Prostatic Diseases 2017 21 :379 - 385; December 27, 2017; 10.1038/s41391-017-0022-9   Abstract | Full Text Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram Raisa S. Pompe, Marco Bandini, Felix Preisser, Michele Marchioni, Emanuele Zaffuto et al. Prostate Cancer and Prostatic Diseases 2018 21 :386 - 393; February 27, 2018; 10.1038/s41391-018-0033-1   Abstract | Full Text Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer M. M. Cherrier, D. J. Cross, C. S. Higano & S. Minoshima Prostate Cancer and Prostatic Diseases 2018 21 :394 - 402; April 27, 2018; 10.1038/s41391-018-0037-x   Abstract | Full Text Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study Huah Shin Ng, Bogda Koczwara, David Roder & Agnes Vitry Prostate Cancer and Prostatic Diseases 2018 21 :403 - 410; May 02, 2018; 10.1038/s41391-018-0036-y   Abstract | Full Text Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients Manish Kohli, Jian Li, Meijun Du, David W Hillman, Scott M. Dehm et al. Prostate Cancer and Prostatic Diseases 2018 21 :411 - 418; June 01, 2018; 10.1038/s41391-018-0043-z   Abstract | Full Text Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? Landon C. Brown, Guru Sonpavde & Andrew J. Armstrong Prostate Cancer and Prostatic Diseases 2018 21 :419 - 430; June 01, 2018; 10.1038/s41391-018-0049-6   Abstract | Full Text Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer Karthik V. Giridhar, Cristobal Sanhueza, David W Hillman, Hassan Alkhateeb, Rachel Carlson et al. Prostate Cancer and Prostatic Diseases 2018 21 :431 - 437; June 01, 2018; 10.1038/s41391-018-0046-9   Abstract | Full Text Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study De Nunzio Cosimo, Brassetti Aldo, Simone Giuseppe, Lombardo Riccardo, Mastroianni Riccardo et al. Prostate Cancer and Prostatic Diseases 2018 21 :438 - 445; June 04, 2018; 10.1038/s41391-018-0054-9   Abstract | Full Text Correspondence Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’ Behfar Ehdaie & Sigrid Carlsson Prostate Cancer and Prostatic Diseases 2018 21 :446 - 447; June 01, 2018; 10.1038/s41391-018-0052-y   Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Prostate Cancer and Prostatic Diseases. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.